SARASOTA, Fla. and NOVATO, Calif., Oct. 26,
An Open Letter from Merdad Parsey, Chief Medical Officer, Gilead Sciences
October 22, 2020 — In less than
CTI BioPharma to Submit a New Drug Application (NDA) for the Accelerated Approval of Pacritinib for the Treatment of Myelofibrosis Patients with Severe Thrombocytopenia
SEATTLE, Sept. 29, 2020 /PRNewswire/ — CTI BioPharma Corp. (Nasdaq: CTIC)
Telix Pharmaceuticals Submits New Drug Application to US FDA for Prostate Cancer Imaging Product
MELBOURNE, Australia and INDIANAPOLIS, Sept. 24, 2020
MacroGenics Announces Publication of Flotetuzumab Interim Phase 1/2 Clinical Trial Results in Blood
ROCKVILLE, MD, Sept. 22, 2020 (GLOBE NEWSWIRE)
Gilead’s Magrolimab, an Investigational Anti-CD47 Monoclonal Antibody, Receives FDA Breakthrough Therapy Designation for Treatment of Myelodysplastic Syndrome
FOSTER CITY, Calif.–(BUSINESS WIRE)–Sep. 15, 2020– Gilead Sciences,
Preventing tuberculosis: A big drug price cut paves the way for global scale-up
Lengthy negotiations ended in good news recently
Priceless cure for baby cost $2.1 million, but insurer paid and now she’s expected to live
Four-month-old Ainsley Cardente smiles, enjoys “helicopter” rides
Computer game may help to predict reuse of opioids
A computer betting game can help predict
Cheap, older gout drug could be a lifesaver after heart attack
(HealthDay)—A cheap drug that’s been around for